Brain and behavior changes with tirzepatide stop and restart
Part of Mental health clinical trials.
This study looks at how your brain and behavior change when you stop and then restart the weight loss drug tirzepatide. It will help researchers understand what happens during treatment breaks.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old.
- You are currently taking the weight loss drug tirzepatide (Mounjaro or Zepbound).
- You are a patient at the UT Southwestern Weight Wellness Clinic.
- You can understand English and give consent.
- You do not have type 2 diabetes, an eating disorder, or a serious neurological condition.
- You have no metal implants or devices that would prevent an MRI (like a pacemaker, metal screws, or clips).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether tirzepatide (a weekly injection for weight loss and diabetes) can prevent atrial fibrillation from coming back after catheter ablation, in people with obesity and heart failure with preserved ejection fraction. It may help by reducing weight and improving heart function.
This study tests whether tirzepatide, a medication that helps with weight loss and blood sugar control, can improve the ability to exercise and daily function in people who have heart failure with reduced pumping strength and are overweight or obese.
This trial tests whether a weekly injection called tirzepatide (a diabetes and weight-loss medication) can help people with obesity and stimulant use disorder reduce stimulant use and lose weight. It aims to see if treating both conditions together improves outcomes.
This study looks at how a weight-loss drug called tirzepatide affects your gut bacteria and digestion after you stop taking it. If you are obese and about to start this drug, joining might help you understand how it changes your body.
This study tests how well adults with overweight or obesity, with or without type 2 diabetes, tolerate switching from their current weight-loss medication (tirzepatide) to a new medicine called zenagamtide. It may help you understand if this new option is easier on your stomach.
This study tests a new drug, NA-931, combined with an existing weight-loss medication (tirzepatide) to see if they work well and are safe for adults who are overweight or obese. It may help you lose weight and improve health conditions related to excess weight.
Hear when a new Substance Use Disorders trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.